FAK–paxillin signalling
Tendon-fibroblast experiments have examined focal-adhesion signalling, cell survival and migration.
Product images are for illustrative reference only. Final label layout and packaging details may vary by batch or production run. Product identity, strength and batch-specific documentation are provided separately and remain product-specific.
NOREXA PEPTIDES / RESEARCH MATERIAL
BPC-15710 mg
Lyophilized Peptide — Single vial
BPC-157 10 mg supplied exclusively as a laboratory research material. Available batch documentation is published only under its corresponding batch record.
In stock
€52 per vial
VOLUME SAVINGS
3+ VIALSSAVE 10%
6+ VIALSSAVE 15%
- RESEARCH FOCUS
- Tissue Repair
QUANTITY
RESEARCH CALCULATOR
Reconstitution & concentration tool
Research areas
FOR LABORATORY RESEARCH USE ONLY.
VERIFY BATCH →Not for human or animal consumption.
Not intended to diagnose, treat, cure or prevent any disease.
SAFETY & EVIDENCE
RESEARCH USE ONLY · Not for human or veterinary use
Preclinical animal studies have reported effects involving haemostatic and platelet-related pathways in experimental models involving anticoagulant or antiplatelet agents including heparin, warfarin, aspirin, clopidogrel and cilostazol.
These findings are preclinical and do not establish a clinical interaction or contraindication profile in humans.
Human safety and interactions between BPC-157 and anticoagulant, antiplatelet, cardiovascular or other medicines have not been adequately established.
The absence of a documented human interaction must not be interpreted as evidence of safety.
NOREXA supplies BPC-157 exclusively for laboratory research and does not recommend or authorise human or veterinary administration.
RESEARCH & TECHNICAL OVERVIEW
BPC-157
10 mg
BPC-157 is a synthetic 15-amino-acid research peptide. It is frequently described in the literature as a stable gastric pentadecapeptide, but the intact synthetic reagent should not be presented as a naturally occurring human peptide without direct evidence.
Published work is dominated by cell and animal models examining fibroblast migration, tendon-related signalling, angiogenesis and nitric-oxide-associated pathways. Robust human evidence remains limited.
RESEARCH SCOPE
For research use only. Not for human or veterinary use. Published findings describe the compound or related research systems; they are not claims about this NOREXA batch.
HANDLING INFORMATION
Storage After
Reconstitution.
- Temperature
- Refrigerate at 2–8°C.
- Light
- Keep sealed and protected from light.
- Stability
- An exact post-reconstitution stability period has not been established for this formulation.
The cited reference does not establish an exact storage period for this product after reconstitution with bacteriostatic water.
MedChemExpress — BPC-157 technical record ↗SCIENTIFIC CONTEXT
Structured.
Source-led.
Longer technical information is grouped for easier reading on desktop and mobile.
01Natural Biological Context+
The sequence has been described as derived from a region associated with gastric proteins or gastric juice research. The laboratory compound itself is synthetic, and claims of an endogenous intact circulating BPC-157 molecule are not established by the references selected here.
02Research Mechanisms+
Growth-hormone receptor expression
Rat tendon-fibroblast studies reported changes in growth-hormone-receptor expression and downstream JAK2 responses.
Vascular and nitric-oxide pathways
Preclinical literature discusses vascular responses and interactions with nitric-oxide systems.
03Research Applications+
- Tendon-fibroblast migration and focal-adhesion signalling assays.
- Preclinical tissue-repair and angiogenesis models.
- Experimental nitric-oxide and vascular-response research.
04Laboratory Research Preparation+
Lyophilized material may require preparation as a laboratory solution before use in an in-vitro assay. The solvent or buffer and working concentration should follow the applicable protocol and documentation for the exact molecular form.
This page intentionally provides no human dosing calculations, syringe-unit conversions, administration route or treatment schedule. Preparation conditions should be established and recorded by qualified laboratory personnel.
INDEPENDENT VERIFICATION
Batch evidence,
without overclaiming.
Purity alone is not enough. NOREXA distinguishes identity, purity and actual quantity, and publishes results only for the exact batch tested.
INDEPENDENT VERIFICATION
BPC-157 10 mgINDEPENDENT REPORT PUBLISHED
- Independent Laboratory
- Janoshik
- Report number
- #234166
Results apply only to the tested sample/batch represented by the linked report. They do not establish results for other products or future batches.
HISTORICAL BATCHES
No historical batch records are currently published for this product.
PRODUCT INFORMATION
Technical
Data.
Verified identity and catalogue information for this NOREXA research material. Unconfirmed fields are omitted.
- Product Name
- BPC-157
- Content
- 10 mg
- Form
- Lyophilized Peptide
- Presentation
- Single vial
- CAS Number
- 137525-51-0
- Peptide Sequence
- GEPPPGKPADDAGLV
- Molecular Formula
- C62H98N16O22
- Molecular Weight
- 1419.5 g/mol
- Research Classification
- Research Use Only
Batch documentation and independent reports are shown only when published for the exact corresponding batch.
CHEMICAL IDENTITY REFERENCE ↗SELECTED SOURCES
Research
Literature.
Selected literature describes the compound and relevant research pathways; it does not constitute testing or endorsement of this NOREXA batch.
- 01Preclinical↗
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Journal of Applied Physiology · 2011
- 02In vitro↗
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts
Molecules · 2014
- 03Review↗
BPC 157 and blood vessels
Current Pharmaceutical Design · 2014
PRODUCT FAQ
BPC-157
questions.
01Is BPC-157 naturally occurring?+
The supplied research compound is synthetic. The selected literature describes its sequence in relation to gastric research, but does not establish the intact synthetic reagent as a naturally occurring human peptide.
02How strong is the evidence base?+
Most published mechanistic evidence is in vitro or preclinical. That limitation is important and is shown directly on this page.
03What pathways are studied?+
Selected studies examine focal-adhesion signalling, fibroblast migration, growth-hormone-receptor expression and vascular or nitric-oxide-related responses.
04Is independent batch verification published?+
Not currently for this product. NOREXA will not display identity, purity or content as verified until an exact batch report is available.
SECTION 01 — STANDARDS
Scientific transparency,
documented for research.
01 / 03Scientific Integrity
Independent analytical results are presented as reported by the testing laboratory, without altering the laboratory’s findings.
02 / 03Batch Traceability
Each batch is assigned a record linking the product to its available technical and independent testing documentation.
03 / 03Quality Documentation
Available batch documentation is organized under the corresponding batch number for clear reference.
